Healthcare, Pharma & Life Sciences

Marengo Completes Enrollment in Key Trial, Adds Two Senior VPs

Image
Marengo Completes Enrollment in Key Trial, Adds Two Senior VPs

Cambridge, Mass. – September 13, 2026 -- Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001 trial evaluating invikafusp alfa across eight distinct PD-1-resistant tumor types, with updated results selected for an oral presentation at the ESMO 2026 Congress in Madrid, October 23-27.

Trial enrollment closes across eight PD-1-resistant tumor types

The monotherapy cohorts covered patients with MSS colorectal cancer, PD-L1-negative non-small cell lung cancer and triple-negative breast cancer, among others resistant to checkpoint blockade. Enrollment continues in standard-of-care combination cohorts, while the company plans to name lead indications for focused development alongside the ESMO data release.

Delta Development Team Launches BloodCOMM Cloud Platform for Blood Chain Tracking

Image
Delta Development Team Launches BloodCOMM Cloud Platform for Blood Chain Tracking

Tucson – September 13, 2026 -- Delta Development Team (DDT) has launched BloodCOMM®, a cloud-based blood management platform designed to digitize and automate blood supply chain tracking for hospitals, blood centers, EMS agencies, and air medical providers.

Platform creates digital identity for every blood unit from collection to disposition

BloodCOMM® uses barcode scanning, AI-powered label recognition, and automated event tracking to monitor blood unit location, temperature, expiration status, inspections, transfers, and excursions throughout the product lifecycle. The system builds a digital cold chain of custody record, capturing patient identifiers, product details, and deviation history as events occur rather than reconstructing them from paper logs or spreadsheets after the fact.

FDA Accepts BLA for Nanoscope's Gene-Agnostic RP Therapy MOGENRY

Image
FDA Accepts BLA for Nanoscope's Gene-Agnostic RP Therapy MOGENRY

Dallas – September 13, 2026 -- The U.S. Food and Drug Administration has accepted and filed the Biologics License Application for MOGENRY, an optogenetic gene therapy from Nanoscope Therapeutics designed to restore vision in retinitis pigmentosa patients with severe vision loss. If approved, MOGENRY would become the first gene-agnostic treatment available for this patient population, which currently has no approved therapy.

RESTORE trial data anchors the regulatory filing

The BLA is supported by the Phase 2b/3 RESTORE trial (NCT04945772), a multicenter, randomized, double-masked, sham-controlled study that met its primary and key secondary endpoints, showing improvements in visual acuity at weeks 52 and 76. No treatment-related serious adverse events were reported. Additional efficacy and safety data come from the earlier Phase 1/2a trial (NCT04919473).

AI Cancer Simulation Tool Wins $3,000 Humane Science Award at ISEF 2026

Image
AI Cancer Simulation Tool Wins $3,000 Humane Science Award at ISEF 2026

Jacksonville, Fla. – September 13, 2026 -- Alan Alwakeel, a recent graduate of Stanton College Preparatory School, received a $3,000 Humane Science Award from the National Anti-Vivisection Society (NAVS) for an AI-powered cancer therapy simulation platform that eliminates the need for animal testing.

Platform simulates cancer treatment efficacy without animal trials

Alwakeel's project, "The Virtual Cell 2.0: Expanding Precision and Personalized Cancer Therapy Through AI-Powered Simulation," applies computational frameworks to evaluate potential cancer treatment outcomes. The tool aims to accelerate how new therapies are developed, tested and deployed by replacing traditional animal-based testing methods with data-driven simulation.

Cionic's TRANSFORM Study Shows 26% Quality-of-Life Gain in Mobility Patients

Image
Cionic's TRANSFORM Study Shows 26% Quality-of-Life Gain in Mobility Patients

San Francisco – September 13, 2026 -- Cionic reported that the first 60 participants in its TRANSFORM study showed an average 26% improvement in health-related quality of life after one month, using the standardized EQ-5D-5L instrument across all five measured dimensions.

Cionic launches 12-month study tracking 1,000 adults with upper motor neuron conditions

The TRANSFORM study follows 1,000 adults with multiple sclerosis, stroke, spinal cord injury, cerebral palsy, and related conditions over 12 months, collecting quality-of-life data through six surveys administered via the Cionic mobile app at onboarding and at one, three, six, nine, and 12 months. The primary endpoint, EQ-5D-5L, measures mobility, self-care, usual activities, pain, and anxiety/depression, while secondary measures track spasticity, urinary incontinence, and fatigue.

Health In Tech Named to Newsweek's Top 100 Mid-Market Companies 2026

Image
Health In Tech Named to Newsweek's Top 100 Mid-Market Companies 2026

Stuart, Fla. – September 13, 2026 -- Health In Tech, Inc. (Nasdaq: HIT) has been named one of Newsweek's America's Greatest Mid-Market Companies 2026, ranking among the 100 highest-scoring U.S. public mid-market firms selected from an initial pool of approximately 4,300 companies.

Newsweek ranking screens nearly 4,300 firms on financial and workforce data

The list, compiled by Newsweek in partnership with Plant-A Insights Group, evaluated companies using financial strength, market performance, workforce data, employee feedback, innovation and patent metrics, independent sustainability assessments, and public records review. A proprietary scoring model narrowed the field to the final 100 honorees for 2026.

CureAlz Adds Four Drug-Development Veterans to Scientific Advisory Board

Image
CureAlz Adds Four Drug-Development Veterans to Scientific Advisory Board

Wellesley Hills, Mass. – – September 13, 2026 -- Cure Alzheimer's Fund (CureAlz) has appointed Drs. Michelle Arkin, Ronald B. DeMattos, Donna M. Huryn, and Kalpana Merchant to its Scientific Advisory Board (SAB), adding decades of pharmaceutical drug-discovery experience to the nonprofit's research-funding strategy.

Board addition brings direct experience from an FDA-cleared Alzheimer's drug

Ronald B. DeMattos spent more than 20 years in neuroscience discovery at Eli Lilly, most recently as Senior Vice President and Chief Scientific Officer for Neurobiologics, where he led development of candidates that advanced to clinical studies including donanemab, the FDA-cleared amyloid-lowering antibody marketed as Kisunla for early Alzheimer's disease.

Natural Field Expands NF TriSolve Platform Into Sleep Wellness

Image
Natural Field Expands NF TriSolve Platform Into Sleep Wellness

Shanghai – September 13, 2026 -- Natural Field has expanded its NF TriSolve® nutraceutical solutions platform into the sleep wellness category with the launch of NF TriSolve® SleepRestore Complex, targeting a growing segment of the global nutrition market.

Natural Field enters sleep wellness with a multi-component nutraceutical formulation

The NF TriSolve® SleepRestore Complex combines multiple functional components into a coordinated formulation designed for sleep-focused nutraceutical applications. The launch marks Natural Field's first entry into the sleep wellness market under its branded NF TriSolve® platform, which converts ingredient expertise, scientific research and formulation capabilities into targeted wellness solutions for global nutrition brands.

Protalix CFO to Present at H.C. Wainwright, Morgan Stanley Healthcare Conferences

Image
Protalix CFO to Present at H.C. Wainwright, Morgan Stanley Healthcare Conferences

Carmiel, Israel – September 13, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) confirmed that Chief Financial Officer Gilad Mamlok will represent the company at two investor conferences in New York City this month.

Mamlok addresses H.C. Wainwright's 28th Annual Global Investment Conference on September 14

The presentation is scheduled for 2:00 p.m. EDT during the three-day event running September 14-16, 2026.

Morgan Stanley's 24th Annual Global Healthcare Conference hosts a fireside chat on September 16

The session is set for 1:05 p.m. EDT and will be streamed via a live audio webcast, with an archived replay available afterward on Protalix's investor relations site.

Sorenson Names Scott Cederbaum Head of Marketing

Image
Sorenson Names Scott Cederbaum Head of Marketing

Salt Lake City – September 13, 2026 -- Sorenson has appointed Scott Cederbaum as Head of Marketing, effective September 13, 2026, tasking him with leading the company's global brand, demand generation and customer lifecycle strategy as accessibility technology and AI converge.

Cederbaum joins with two decades of revenue and growth leadership across education, technology and subscription businesses

He most recently served as Chief Revenue Officer at Blueprint Prep, where he oversaw enterprise-wide revenue strategy, marketing, sales and pricing. Cederbaum has also held CMO and senior growth roles building marketing organizations, running digital transformation initiatives, and using data and analytics to drive customer acquisition and retention.